Abstract
Briefly stated my point is that the well-being of each person in a community conceived abstractly may be all too easily sacrificed for the sake of the abstraction. Physicians may offer critically ill patients places in programs of experimental treatment, but there is commonly a catch to the offer. To take part in a program of clinical experiment a patient must not only risk a possible failure of a fresh drug and the chance of destructive side effects from the drug, but the patients must risk only getting the traditional treatment along with a placebo rather than the experimental drug. Placebo control, double blind critical protocols for testing effects of fresh drugs on critically ill patients are a commonplace. I question the scientific objectivity of the protocols and the underlying ethic, and suggest use of alternate protocols. Experimental tests in the treatment gram-negative bacteria blood infections, muscular dystrophy, and AIDS and AIDS-related diseases are examples.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Centers for Disease Control. (1990). Increase in national hospital discharge survey rates for septicemia—United States, 19791987.Morbidity & Mortality Weekly Report, 39: 31–34.
Gorelick, K. J., Jacobs, R., Chmel, H., et l. (1989). Efficacy results of a randomized multicenter trial of E5 antiendotoxin monoclonal antibody in patients with suspected gram-negative sepsis.Abstracts of the 29th Interscience Conference on Antimicrobial Agents & Chemotherapy, 2. [Xoma's experimental drug is E5. The drug's trade name is ‘Xomazyme’].
Greenman, R. L., Schein, R. M. H., Martin, M. A., et al. (1991). A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis.Journal of the American Medical Association, 266: 1097–1102.
Hilts, P. J. (1990, June 23). Tests of new AIDS drug assailed at parley.New York Times, A24. [Report on private clinical tests of Compound Q with non-standard control. Controls are the records of previous patients against a longitudinal track of health characteristics of patients].
Kahn, J. O., Kaplan, L. D., Gambertoglio, J. G., et al. (1990a). A phase I study of GLQ223 in subjects with AIDS and ARC [AIDS-related complex].Abstracts of the 6th International Conference on AIDS, 3: 202. [Compound Q's experimental name is GQ223. Phase I studies cover short term safety and pharmacokinetics, phase II tests short term safety and effectiveness, and dosage level].
Kahn, J. O., Kaplan, L. D., Gambertoglio, J. G., et al. (1990b). Safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: A phase I study.AIDS, 4: 1197–1204.
Kolata, G. (1989, September 20). Private study of AIDS drug: Praise and warning.New York Times, A21. [Initial report on clinical tests of Compound Q with nonstandard control]
Kolata, G. (1990, October 21). A critique of pure reason, a passion to survive: Cheating on AIDS trials. Can desperately ill people be expected to feel a moral obligation to the demanding rigors of the scientific method?New York Times, E4.
Kolata, G. (1991a, February 22). Drug is found to prevent deadly pneumonia: New hope on leading killer of AIDS patients.New York Times, A15. [Report on cotrimoxazole in preventingPneumocystis Carinii pneumonia].
Kolata, G. (1991b, May 2). First effort to treat muscular dystrophy: Critics of an experiment on humans cite ethical problems.New York Times, B10.
Law, P. K., Bertorini, T, Goodwin, T. G., et al. (1990). Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy.Lancet, 336: 114–115.
Law, P. K., Goodwin, T. G., Li, H. J., et al. (1990a). Myoblast transfer improves muscle genetics, structure, function and normalizes the behavior and life-span of dystrophic mice.Advances in Experimental Medicine & Biology, 280: 74–84.
Law, P. K., Goodwin, T. G., Li, H. J., et al. (1990b). Plausible structural, functional, behavioral, biochemical transformations following myoblast transfer therapy.Advances in Experimental Medicine & Biology, 280: 241–249.
Leary, W. E. (1991, November 14). F.D.A. says it plans to quicken process for approving new drugs: “Millions of lives and billions of dollars.”New York Times, B14. [Response to Presidential advisory panel reports urging speeding of the drug approval process].
National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS. (1990, August).Final report. Bethesda, MD: National Institutes of Health.
Pear, R. (1990, August 16). Faster approval of AIDS drugs is urged. “Time is running out,” an advisory panel says.New York Times, B12. [Report on National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS].
Pollack, A. (1989, September 19). Advance is seen in treating infections.New York Times, C5. [Report on Xoma's drug E5].
Pollack, A. (1990, April 10). Drug for shock from infection advances.New York Times, D1 & D13. [Report on Centocor's drug HA-1A].
Ruskin, J. & LaRiviere, M. (1991). Low-dose co-trimoxazole for prevention ofPneumocystis Carinii pneumonia in human immunodeficiency virus disease.Lancet, 337: 468–471. [The trade names for co-trimoxazole are “Bactrim” and “Septra”].
Santayana, G. (1896/1955).The sense of beauty: Being the outlines of aesthetic theory. New York, NY: Dover Publications.
Ziegler, E. J., Fisher, C. J., Sprung, C., et al. (1990). Prevention of death from gram-negative bacteremia and sepsis by HA-1A, a human monoclonal antibody specific for lipid A of endotoxin: Results of phase III trial.Clinical Research, 38: 304A. [Cetocor's experimental drug is HA-1A. The drug's trade name is “Centoxin”].
Ziegler, E. J., Fisher, C. J., Sprung, C., et al. (1991). Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial.New England Journal of Medicine, 324: 429–436.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosenberg, L.T. We have a prejudice against ourselves—Sentiment, ethics, and reason. J Med Hum 14, 5–14 (1993). https://doi.org/10.1007/BF01138156
Issue Date:
DOI: https://doi.org/10.1007/BF01138156